Surrey Heartlands

Joint Formulary & PAD

Mesalazine - Inflammatory bowel disease

You are here : Home > Formulary Search > Mesalazine - Inflammatory bowel disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Gastro-resistant tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
Preferred
Prescribe by brand.: Octasa or Salofalk gastro resistant tablets (or Salofalk granules) are 1st line for new patients Asacol tablets are non-formulary
 

Status 2

Green (see narrative)
Formulations :
  • Suppositories
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
Prescribe by brand: Octasa, Salofalk, Pentasa
 

Status 3

Green (see narrative)
Formulations :
  • Modified release tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
R
Restrictions / Comments :
Important
Mezevant XL - Reserve for patients with a high pill burden.
 

Status 4

Green (see narrative)
Formulations :
  • Granules (slow release)
  • Modified release tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
Preferred
Prescribe by brand: Salofalk granules are a 1st-line option for new patients. Pentasa modified-release tablets and granules for patients who require upper GI release.
 

Status 5

Green (see narrative)
Formulations :
  • Enema
  • Foam enema
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
Prescribe by brand: Pentasa / Salofalk enema
 

Status 6

Non Formulary
Formulations :
  • Gastro-resistant tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
Asacol 400mg gastro resitsant tablets have been discontinued. The 800mg tablets are non-formulary.

Documentation

Guidelines (Local)
Ulcerative Colitis (Pathway 2) - Primary care - May 2018.pdf

PAD Profile

ChemicalSubstance :
Mesalazine
Indication :
Inflammatory bowel disease
Group Name :
Keywords :
Ulcerative colitis, UC, IBD, aminosalicylates, chronic bowel disorders
Brand Names Include :
Octasa, Salofalk Granules, Pentasa, Mezavant, Zintasa
Important Information :
Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Inflammatory bowel disease
Supporting Documents :
1
Traffic Light Entries :
6

Other Indications

Below are listed other indications that Mesalazine is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Inflammatory bowel disease.

Committee Recommendations (1)

07 Jul 21 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Mesalazine therapy is included within the locally agreed pathway for Ulcerative Colitis (see pathway document below).


Mesalazine therapy should be prescribed by BRAND. The following brands have been considered by the APC: 

  • Salofalk® gastro-resistant tablets and granules - 1st line for new patients
  • Octasa® MR gastro-resistant tablets - 1st line for new patients
  • Pentasa® modified-release tablets and granules -  1st line for patients who require upper GI release
  • Mezavant® XL tablets -  Alternative choice for patients with high pill burden

Choice is dependent on required site of release and factors that may aid adherence to therapy.  Prescribe by brand to ensure continuation of those chosen properties

Asacol® MR gastro-resistant tablets are non-formulary and least cost-effective option - can continue in existing patients with good disease control (see separate page https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/6208).  Octasa® MR has the same release properties as Asacol® MR